COMMUNIQUÉS West-GlobeNewswire

Emerald Health Therapeutics Announces Discharge of Litigation

30/01/2019 - 13:00

VANCOUVER, British Columbia, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite [...]

Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis

30/01/2019 - 13:00

MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet™ platform delivery technology Company to host [...]

Trevena Announces $10 Million Registered Direct Offering of Common Stock

30/01/2019 - 13:00

CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused institutional investors, [...]

Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

30/01/2019 - 13:00

Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of [...]

Terveystalo Plc: Proposals of the Shareholders Nomination Board to the Annual General Meeting 2019

30/01/2019 - 12:01

Terveystalo Plc Stock Exchange Release 30 January 2019 at 13:00 EET The Shareholders' Nomination Board of Terveystalo has submitted its proposal on the Board of Directors to the Annual General Meeting 2019. Proposal on [...]

Release date of annual report 2018 for ALK and audio cast

30/01/2019 - 09:47

On Thursday, 7 February 2019, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its annual report for 2018. ALK will host a meeting for analysts and institutional investors that day at 12.30 p.m. (CET) at which [...]

Enzymatica AB: First patients included in large placebo-controlled multicentre study on ColdZyme

30/01/2019 - 08:31

Press release 30 January 2019 First patients included in large placebo-controlled multicentre study on ColdZyme Enzymatica has initiated a prospective double-blind, placebo-controlled multicentre study to evaluate the [...]

Changes to the Nomination Committee for Immunicum AB (publ)

30/01/2019 - 08:01

Press Release 30 January 2019 Changes to the Nomination Committee for Immunicum AB (publ) Immunicum AB (publ) (the "Company" or "Immunicum") announced the composition of the Nomination Committee on 19 October 2018. As a [...]

Curetis’ Unyvero Application Cartridges Receive Regulatory Approvals in Malaysia and Thailand

30/01/2019 - 07:50

HPN Cartridge approved in Malaysia; HPN, BCU Cartridges approved in Thailand Further commercial roll-out of Unyvero in ASEAN region by partner Acumen Research Laboratories facilitated Near-term Chinese NMPA submission [...]

Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)

30/01/2019 - 07:14

Orphazyme A/S Company announcement No. 01/2019 Company Registration No. 32266355 Primary endpoint shows 74% reduction in disease progression after 12 months compared to placebo control (p-value =0.0506) Biomarker [...]

Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

30/01/2019 - 07:02

Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+102% cc) Oncology BU [...]

En 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entreprise

30/01/2019 - 07:02

Hausse du chiffre d'affaires net de 5% (tcc[1], +6% USD) en 2018, soutenue par l'excellente performance des moteurs de croissance : Pharmaceuticals: cette unité opérationnelle a progressé de 7% (tcc), impulsée par [...]

Bone Therapeutics SA: Information on the total number of voting rights and shares

30/01/2019 - 07:00

Regulated information Gosselies, Belgium, 30 January 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]

Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions

30/01/2019 - 07:00

Information réglementée Gosselies, Belgique, le 30 janvier 2019, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins [...]

ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring

29/01/2019 - 23:40

SINGAPORE, Jan. 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, today announced [...]

Inspire Medical Systems, Inc. Announces FDA Approval of New Sensing Lead

29/01/2019 - 22:15

MINNEAPOLIS, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]

Stryker reports 2018 results and 2019 outlook

29/01/2019 - 22:06

Kalamazoo, Michigan, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2018 and 2019 outlook: Fourth Quarter Highlights • Reported net sales [...]

Heather Rowe Named Dynavax’s Vice President of Investor Relations and Corporate Communications

29/01/2019 - 22:05

BERKELEY, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology [...]

GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease

29/01/2019 - 22:05

—Company Plans to Submit NDA for Voxelotor Under FDA Accelerated Approval Pathway Later This Year— SOUTH SAN FRANCISCO, Calif. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) [...]